A third athlete has tested positive for performance-enhancing drugs during the 2026 Asian Games in Aichi-Nagoya, Japan. The latest case involves Nodirbek Shavkatov, an Uzbek mixed martial arts (MMA) fighter who earned a bronze medal at the event. Shavkatov tested positive for meldonium, a substance that was previously banned by the World Anti-Doping Agency (WADA) but was removed from the prohibited list in 2021. However, it remains restricted in certain sports and under specific conditions. Meldonium, originally developed to treat heart conditions, has been linked to performance enhancement in endurance sports. Its use has been controversial, with several high-profile athletes facing sanctions in the past. Shavkatov has been provisionally suspended while further tests and investigations are conducted to determine the validity of the positive result. The doping control process is a standard procedure at international sporting events to ensure fair play and compliance with anti-doping regulations. Athletes who test positive are typically suspended until the outcome of an appeal or further testing. This marks the third doping violation at the 2026 Asian Games, raising concerns about drug use in competitive sports. The Asian Games, one of the largest multi-sport events in the world, bring together athletes from across Asia. The presence of multiple doping cases has sparked discussions about the effectiveness of current drug-testing protocols and the need for continued vigilance in maintaining the integrity of the competition.